Literature DB >> 23760752

Over-expression of Mcl-1 impairs the ability of ATRA to induce growth arrest and differentiation in acute promyelocytic leukemia cells.

Jing Yang1, Takayuki Ikezoe2, Chie Nishioka1, Akihito Yokoyama1.   

Abstract

Exposure of acute promyelocytic leukemia (APL) cells to all-trans retinoic acid (ATRA) increases levels of Mcl-1, however, the implication of ATRA-mediated expressions of Mcl-1 in these cells remains to be fully elucidated. This study found that exposure of NB4 and PL-21 cells to ATRA increased levels of Mcl-1 in association with phosphorylation of c-jun N-terminus kinases. Down-regulation of Mcl-1 by a small interfering (siRNA) or an inhibitor of JNK significantly potentiated the ability of ATRA to induce differentiation and apoptosis in these cells. On the other hand, the anti-leukemia effects of ATRA were blunted when Mcl-1 was forced expressed in NB4 and PL-21 cells as well as leukemia cells isolated from individuals with APL. Furthermore, down-regulation of Mcl-1 by an siRNA sensitized non-APL U937 and KG-1 leukemia cells to ATRA-mediated differentiation and apoptosis. Taken together, inhibition of Mcl-1 might be useful to potentiate the action of ATRA in APL as well as non-APL AML cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23760752     DOI: 10.1007/s10495-013-0872-0

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  7 in total

1.  Therapeutic potential of Bcl-xL/Mcl-1 synthetic inhibitor JY-1-106 and retinoids for human triple-negative breast cancer treatment.

Authors:  Mariarita Perri; Jeremy L Yap; Steven Fletcher; Erika Cione; Maureen A Kane
Journal:  Oncol Lett       Date:  2018-03-14       Impact factor: 2.967

2.  RaRF confers RA resistance by sequestering RAR to the nucleolus and regulating MCL1 in leukemia cells.

Authors:  H Youn; H-K Lee; H-R Sohn; U-H Park; E-J Kim; B Youn; S-J Um
Journal:  Oncogene       Date:  2017-09-25       Impact factor: 9.867

3.  Changes in expression of WT1 during induced differentiation of the acute myeloid leukemia cell lines by treatment with 5-aza-2'-deoxycytidine and all-trans retinoic acid.

Authors:  Lili Xiang; Jiahe Zhou; Weiying Gu; Rong Wang; Jiang Wei; Guoqiang Qiu; Jiannong Cen; Xiaobao Xie; Zixing Chen
Journal:  Oncol Lett       Date:  2015-12-23       Impact factor: 2.967

4.  BCL-xL/MCL-1 inhibition and RARγ antagonism work cooperatively in human HL60 leukemia cells.

Authors:  Mariarita Perri; Jeremy L Yap; Jianshi Yu; Erika Cione; Steven Fletcher; Maureen A Kane
Journal:  Exp Cell Res       Date:  2014-08-01       Impact factor: 3.905

5.  Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells.

Authors:  Rui Wang; Lijuan Xia; Janice Gabrilove; Samuel Waxman; Yongkui Jing
Journal:  Clin Cancer Res       Date:  2015-10-12       Impact factor: 12.531

Review 6.  The application of BH3 mimetics in myeloid leukemias.

Authors:  Narissa Parry; Helen Wheadon; Mhairi Copland
Journal:  Cell Death Dis       Date:  2021-02-26       Impact factor: 8.469

7.  A novel PAD4/SOX4/PU.1 signaling pathway is involved in the committed differentiation of acute promyelocytic leukemia cells into granulocytic cells.

Authors:  Guanhua Song; Lulu Shi; Yuqi Guo; Linchang Yu; Lin Wang; Xiaoyu Zhang; Lianlian Li; Yang Han; Xia Ren; Qiang Guo; Kehong Bi; Guosheng Jiang
Journal:  Oncotarget       Date:  2016-01-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.